Regulation of pulmonary vascular smooth muscle contractility in pulmonary arterial hypertension: Implications for therapy

Melissa A. Lyle, Jonathan P. Davis, Frank V. Brozovich

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

There are two primary components that produce pulmonary arterial hypertension (PAH); aberrant structural changes (smooth muscle cell proliferation, smooth muscle cell hypertrophy, and the deposition of matrix proteins within the media of pulmonary arterial vessels), and excess vasoconstriction. However, in PAH, the target and aim of all current therapeutic agents is to reduce the contractility of the pulmonary vasculature; prostaglandins, phosphodiesterase inhibitors, guanylate cyclase stimulators, endothelin antagonists, NO inhalation and Rho kinase inhibitors all influence signaling pathways in the pulmonary vascular smooth muscle to decrease vasoconstriction, and hence, pulmonary vascular resistance (PVR). This review will therefore primarily focus on discussing the signaling pathways regulating contractility in pulmonary vascular smooth muscle, the mechanism for current treatments, as well as highlighting potential targets for the development of novel therapies.

Original languageEnglish (US)
Article number614
JournalFrontiers in Physiology
Volume8
Issue numberAUG
DOIs
StatePublished - Aug 23 2017

Fingerprint

Vascular Smooth Muscle
Pulmonary Hypertension
Lung
Vasoconstriction
Smooth Muscle Myocytes
Tunica Media
Prostaglandin Antagonists
rho-Associated Kinases
Phosphodiesterase Inhibitors
Guanylate Cyclase
Therapeutics
Vascular Resistance
Hypertrophy
Inhalation
Cell Proliferation
Proteins

Keywords

  • Contractility
  • Signaling pathways
  • Therapeutics
  • Vascular diseases
  • Vascular resistance

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Regulation of pulmonary vascular smooth muscle contractility in pulmonary arterial hypertension : Implications for therapy. / Lyle, Melissa A.; Davis, Jonathan P.; Brozovich, Frank V.

In: Frontiers in Physiology, Vol. 8, No. AUG, 614, 23.08.2017.

Research output: Contribution to journalReview article

@article{5de0c8a0a4174eb79216e06527f4251e,
title = "Regulation of pulmonary vascular smooth muscle contractility in pulmonary arterial hypertension: Implications for therapy",
abstract = "There are two primary components that produce pulmonary arterial hypertension (PAH); aberrant structural changes (smooth muscle cell proliferation, smooth muscle cell hypertrophy, and the deposition of matrix proteins within the media of pulmonary arterial vessels), and excess vasoconstriction. However, in PAH, the target and aim of all current therapeutic agents is to reduce the contractility of the pulmonary vasculature; prostaglandins, phosphodiesterase inhibitors, guanylate cyclase stimulators, endothelin antagonists, NO inhalation and Rho kinase inhibitors all influence signaling pathways in the pulmonary vascular smooth muscle to decrease vasoconstriction, and hence, pulmonary vascular resistance (PVR). This review will therefore primarily focus on discussing the signaling pathways regulating contractility in pulmonary vascular smooth muscle, the mechanism for current treatments, as well as highlighting potential targets for the development of novel therapies.",
keywords = "Contractility, Signaling pathways, Therapeutics, Vascular diseases, Vascular resistance",
author = "Lyle, {Melissa A.} and Davis, {Jonathan P.} and Brozovich, {Frank V.}",
year = "2017",
month = "8",
day = "23",
doi = "10.3389/fphys.2017.00614",
language = "English (US)",
volume = "8",
journal = "Frontiers in Physiology",
issn = "1664-042X",
publisher = "Frontiers Research Foundation",
number = "AUG",

}

TY - JOUR

T1 - Regulation of pulmonary vascular smooth muscle contractility in pulmonary arterial hypertension

T2 - Implications for therapy

AU - Lyle, Melissa A.

AU - Davis, Jonathan P.

AU - Brozovich, Frank V.

PY - 2017/8/23

Y1 - 2017/8/23

N2 - There are two primary components that produce pulmonary arterial hypertension (PAH); aberrant structural changes (smooth muscle cell proliferation, smooth muscle cell hypertrophy, and the deposition of matrix proteins within the media of pulmonary arterial vessels), and excess vasoconstriction. However, in PAH, the target and aim of all current therapeutic agents is to reduce the contractility of the pulmonary vasculature; prostaglandins, phosphodiesterase inhibitors, guanylate cyclase stimulators, endothelin antagonists, NO inhalation and Rho kinase inhibitors all influence signaling pathways in the pulmonary vascular smooth muscle to decrease vasoconstriction, and hence, pulmonary vascular resistance (PVR). This review will therefore primarily focus on discussing the signaling pathways regulating contractility in pulmonary vascular smooth muscle, the mechanism for current treatments, as well as highlighting potential targets for the development of novel therapies.

AB - There are two primary components that produce pulmonary arterial hypertension (PAH); aberrant structural changes (smooth muscle cell proliferation, smooth muscle cell hypertrophy, and the deposition of matrix proteins within the media of pulmonary arterial vessels), and excess vasoconstriction. However, in PAH, the target and aim of all current therapeutic agents is to reduce the contractility of the pulmonary vasculature; prostaglandins, phosphodiesterase inhibitors, guanylate cyclase stimulators, endothelin antagonists, NO inhalation and Rho kinase inhibitors all influence signaling pathways in the pulmonary vascular smooth muscle to decrease vasoconstriction, and hence, pulmonary vascular resistance (PVR). This review will therefore primarily focus on discussing the signaling pathways regulating contractility in pulmonary vascular smooth muscle, the mechanism for current treatments, as well as highlighting potential targets for the development of novel therapies.

KW - Contractility

KW - Signaling pathways

KW - Therapeutics

KW - Vascular diseases

KW - Vascular resistance

UR - http://www.scopus.com/inward/record.url?scp=85028352956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028352956&partnerID=8YFLogxK

U2 - 10.3389/fphys.2017.00614

DO - 10.3389/fphys.2017.00614

M3 - Review article

AN - SCOPUS:85028352956

VL - 8

JO - Frontiers in Physiology

JF - Frontiers in Physiology

SN - 1664-042X

IS - AUG

M1 - 614

ER -